214 related articles for article (PubMed ID: 34157803)
1. [Research Progress of Immune Checkpoint Inhibitors
in Malignant Pleural Mesothelioma].
Huang Y; Meng Q
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):441-446. PubMed ID: 34157803
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
3. Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
Hu ZI; Ghafoor A; Sengupta M; Hassan R
Cancer; 2021 Apr; 127(7):1010-1020. PubMed ID: 33620732
[TBL] [Abstract][Full Text] [Related]
4. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
[TBL] [Abstract][Full Text] [Related]
5. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
Hotta K; Fujimoto N
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
[TBL] [Abstract][Full Text] [Related]
6. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
[TBL] [Abstract][Full Text] [Related]
8. Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.
Marcq E; Audenaerde JRV; Waele J; Jacobs J; Loenhout JV; Cavents G; Pauwels P; Meerbeeck JPV; Smits EL
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31455014
[TBL] [Abstract][Full Text] [Related]
9. Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma.
Zhang D; Liang J; Lv Y; Huang X; Guo W
Medicine (Baltimore); 2022 Dec; 101(52):e32459. PubMed ID: 36596035
[TBL] [Abstract][Full Text] [Related]
10. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
Bronte G; Delmonte A; Burgio MA; Verlicchi A; Puccetti M; Bravaccini S; Cravero P; Tumedei MM; Diano D; Rossi G; Ulivi P; Martinelli G; Crinò L
Lung Cancer; 2020 Apr; 142():47-50. PubMed ID: 32088605
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
[TBL] [Abstract][Full Text] [Related]
12. [Advances in Immunotherapy for Malignant Pleural Mesothelioma].
Chi Y; Liu Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):259-265. PubMed ID: 35477190
[TBL] [Abstract][Full Text] [Related]
13. Novel therapies for malignant pleural mesothelioma.
Scherpereel A; Wallyn F; Albelda SM; Munck C
Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
[TBL] [Abstract][Full Text] [Related]
15. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
[TBL] [Abstract][Full Text] [Related]
16. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
17. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.
Gray SG
BMC Pulm Med; 2021 May; 21(1):148. PubMed ID: 33952230
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for immunotherapy in malignant pleural mesothelioma?
Tartarone A; Lerose R; Aieta M
Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
[TBL] [Abstract][Full Text] [Related]
20. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
Uprety D
Clin Lung Cancer; 2021 Mar; 22(2):71-73. PubMed ID: 33358660
[No Abstract] [Full Text] [Related]
[Next] [New Search]